October 7, 2016
Mylan Inks $465M Deal Over EpiPen Rebates
Mylan Inc. on Friday said it has reached a $465 million deal with the U.S. Department of Justice to resolve an investigation into its controversial classification of allergy treatment EpiPen as a generic drug for purposes of Medicaid rebates, but the settlement didn't immediately calm anger.
No comments:
Post a Comment